IMMUTEP LIMITED — Investor Presentation 2014

Oct 12, 2014

INVESTOR UPDATE by EDITION13

by OCTOBER 2014

==> picture [131 x 150] intentionally omitted <==

Message from the Chair and CEO

Dear Shareholders,

• A Phase II program in cancer immunotherapy for metastatic breast cancer partnered with Eddingpharm and licensed in China and Taiwan (Immutep has retained the rights to commercialise IMP321 in all other parts of the world);

We are very pleased to bring you this latest newsletter, which is focused on our recently announced agreement to acquire the French biotechnology company Immutep SA (“Immutep”).

Lucy Turnbull, AO

• A Phase I program in autoimmune diseases partnered with GlaxoSmithKline; and

==> picture [131 x 150] intentionally omitted <==

• A pre-clinical program in cancer immunotherapy partnered with CoStim (Novartis).

Following a long and rigorous search process, this is the first major acquisition as part of our corporate strategic development program and is the most important announcement for Prima BioMed in recent times. The acquisition addresses some of the general rules for success in the biotech industry and positions Prima well for future growth.

As part of the agreement with these partners, Prima stands to earn potential milestone payments at various stages in their development cycle as well as royalties once the products are marketed. While the details of two of the agreements remain confidential, total achievable milestone payments from GSK are up to approximately US$100M. In addition, Immutep currently generates modest revenues from sales of LAG-3 research reagents and has a strong patent portfolio with 11 patent families protecting the LAG-3 technology.

CEO Marc Voigt

We firmly believe that for a small biotechnology company like Prima to enhance its commercial and investor appeal it needs to develop a strong portfolio of diverse and promising product candidates in its area of expertise.

Fundamentally, we believe that the acquisition of Immutep is a very attractive deal for Prima with potential to unlock tremendous value for Prima and its shareholders as the portfolio is developed.

CVac[TM] represents a very promising personal immunotherapy cancer vaccine. In Immutep we have found the right technology within cancer immunotherapy to complement CVac yet bring a new, diverse pipeline of products. In this way we generate a more diverse and therefore balanced portfolio of opportunities in cancer immunotherapy.

[continued on p.2]

These products are being developed in partnership with some of the world’s largest pharmaceutical companies, who bear their development costs, thus decreasing our risk. These include:

>> In this Issue:

• Message from the Chair and CEO Immunotherapy overview About Immutep

• Introducing Professor Frédéric Triebel

==> picture [299 x 71] intentionally omitted <==

[continued from p.1]

Message from the Chair and CEO

It is extremely important not to do a deal for the sake of it, but to do the right deal which is affordable and which leverages the expertise of both parties. In terms of value, the acquisition follows an intensive assessment and due diligence process to ensure we secured the right transaction for Prima. This included an independent valuation opinion from KPMG.

To put the approximately US$28M purchase price into perspective, according to research company Evaluate Pharma, the average price for an upfront licensing payment for a Phase II asset in oncology is US$38M. In addition to this amount, there would typically be future milestone payments and royalties owing.

Cancer immunotherapy is one of the most active biotech market segments, as illustrated by the recent transaction of Boehringer Ingelheim GmbH, which licensed a single product in a Phase Ib trial in cancer for an upfront payment of €35M and total milestones of up to €430M plus royalties.

We therefore believe that by acquiring Immutep as a whole, we have secured an extremely compelling value proposition.

In terms of expertise, Prof. Frédéric Triebel, Immutep’s founder and an eminent scientist in immunotherapy, will join Prima as our new Chief Scientific Officer. He will bring with him a small team which is highly complementary to Prima’s and allows us to bring certain functions in-house that we previously outsourced, including research and immune monitoring.

Meanwhile, with its considerable expertise in clinical development, manufacturing and quality control, Prima’s team is able to support both programs. So there are also good synergies to be realised.

Financing

As at 30 June 2014, Prima had A$23.2M in cash and term deposits. In order to mitigate the immediate funding risk of the transaction, we negotiated a risk-balanced financing agreement with Bergen Asset Management from New York, USA. This should allow us to fund our ongoing operational costs and preserve our cash balance to ensure we remain in a sound financial position. It also brings a major US institutional investor on to our share register. We have negotiated a flexible funding arrangement with Bergen in which Prima has retained the right to pause the monthly tranche schedule or

terminate the funding agreement at any time. In addition to this funding, we would benefit from potential milestone payments from Immutep’s development partners.

Prima has agreed to pay Immutep shareholders an aggregate amount of up to approximately US$28M. Of the US$18M cash component, US$10.8M will be paid on completion. The remaining 40% of the cash component, as well as a part of the warrants, are deferred and mainly subject to the achievement of predetermined milestones. The shares and most of the warrants will be issued to Immutep shareholders on completion and are subject to escrow and volume selling limitations.

The completion of the acquisition is conditional on Prima obtaining shareholder approval to increase our share placement capacity. We will ask for this approval at our next Annual General Meeting, in November 2014. We strongly encourage our shareholders to vote in favour of all the resolutions contained in this year’s Notice of Meeting to support and enable us to successfully complete the acquisition of Immutep, a step which we strongly believe is in the best interest of our shareholders.

Outlook

The mission of our Company will be broadened to become a leader in the growing field of cancer immunotherapy, with potential for addition of therapies outside the field of cancer vaccines.

The past months have been challenging for Prima and our shareholders but we believe that we have the opportunity to create significant value from our expanded cancer immunotherapy portfolio.

We would like to thank you all for your support in the past and also to ask for your patience in this critical, but highly promising phase of building a reinvigorated Prima with a diversified pipeline of promising immunooncology products.

We will keep shareholders updated along the way and look forward to seeing some of you at our upcoming AGM in November.

Yours sincerely, Lucy Turnbull, Chair Marc Voigt, Chief Executive Officer

2

==> picture [596 x 71] intentionally omitted <==

Immunotherapy overview

The immune system is often compared with a car – in particular its ignition, acceleration and braking. Early experiments in immunotherapy focused on acceleration, or ‘stepping on the gas’ of the immune system.

perhaps even combining them, the best treatment method will bring the most beneficial effect for patients.

As Prima is currently active in the field of cellular therapies which are a form of cancer vaccine, it makes strategic sense to extend the portfolio to include other alternative technologies in cancer immunotherapy.

Researchers then discovered that the immune system has brakes – and the pressure on the brakes might need to be reduced to allow the accelerator to work.

By acquiring the Immutep portfolio, Prima is now active in all three key areas of cancer immunotherapy, as illustrated in figure 1. In addition IMP731 shall be tested by GlaxoSmithKline in autoimmune diseases.

==> picture [456 x 294] intentionally omitted <==

----- Start of picture text -----

The field of cancer immunotherapy compris-
es cancer vaccines, antibody therapies
and cytokine therapies. By using
different treatment therapies and diseases.
Turn on the Release the
immune brakes
Cellular therapy, system Immune checkpoint agents,
Antibody therapy Antibody therapy
... ...
CVac IMP701
Push the
gas
Figure 1 Cytokine therapy,
Antibody therapy
...
IMP321
----- End of picture text -----

increasingly being recognised in the scientific and medical community as an optimal approach for fighting cancer.

The LAG-3 technology of Immutep includes a recombinant protein and two antibodies being developed by its partners. Other well-known molecules in this class include CTLA-4, PD-1 and PD-L1. Although each of the Immutep products and CVac are stand-alone products, they can potentially be combined with other chemotherapies or immunotherapies. Combination immunotherapy is

Citi Research has forecast that immunotherapies have the potential to generate up to US$35B in annual revenue by 2023. This level of forecast growth is underpinning the excitement in the immunotherapy field around the world.

==> picture [512 x 114] intentionally omitted <==

3

==> picture [596 x 71] intentionally omitted <==

About Immutep

Immutep is a French private biotechnology company which has been operating for over a decade in the fastgrowing field of immunotherapy. The company is well-advanced in the clinic and has a number of commercial partnerships with large pharmaceutical companies and additional products in pre-clinical research.

Immunotep’s products are based on novel pathways in immune control. These technologies were developed by Immutep’s founding Scientific and Medical Director, Prof. Frédéric Triebel. This work was conducted in collaboration between one of the largest cancer centres worldwide, the Gustave Roussy Institute, and Merck-Serono. The Company’s products are based on novel pathways in the Lymphocyte Activation Gene-3 (LAG-3) immune control mechanism. LAG-3 has been shown to be involved in a number of T cell regulatory pathways, in some cases activating and in other cases suppressing the effects of immune responses.

Complementary approaches of therapies that the company is developing include:

==> picture [501 x 181] intentionally omitted <==

----- Start of picture text -----

IMP321 IMP731 IMP701
• recombinant protein, to be used as • depleting anti-LAG-3 antibody • antagonist anti LAG-3 antibody
a monotherapy, an adjuvant or in
• depletes activated T cells • binds to receptor on suppressive
combination with chemotherapy
in autoimmue disease leading to T cells to block their inhibitory
• a first in class antigen presenting long term immunosuppression signal. Also gives rise to T Cell
cell (APC) activator • in clinical Phase I trial for profileration in a similar manner
to anti CTLA-4 and anti PD-1
• repeated IMP321 injection in autoimmune disease
antibodies in cancer patients
Phase II lead to strong anti-tumor
• licensed to GSK
cell response in cancer patients • pre-clinical candidate licensed
to CoStim (Novartis)
• Partnered in China with
Eddingpharm
----- End of picture text -----

Combined business development pipeline

==> picture [502 x 264] intentionally omitted <==

----- Start of picture text -----

Partner Preclinical Phase I Phase II a Phase II b Phase III Indication
Neopharm CVac Ovarian Cancer
Group (for Israel)
Neopharm CVac Pancreatic Cancer
Group (for Israel)
Eddingpharm IMP321 Metastatic Breast Cancer
(for China) + Chemotherapy
Eddingpharm IMP321 Metastatic Renal Cell
(for China) Carcinoma & others
GlaxoSmithKline IMP731 Autoimmune disease
(WW)
CoStim (Novartis) IMP701 Cancer and chronic
(WW) infectious disease
----- End of picture text -----

4

==> picture [596 x 71] intentionally omitted <==

==> picture [119 x 161] intentionally omitted <==

Introducing Professor Frédéric Triebel

Director of an INSERM (large public health organisation) Unit from 1991 to 1996.

Prima BioMed is pleased to welcome Prof. Frédéric Triebel as part of the leadership team, which he will join as Chief Scientific Officer.

First trained as a clinical haematologist, Prof. Triebel holds a PhD in immunology (Paris University) and successfully developed several research programs in immunogenetics and immunotherapy, leading to 144 publications and 16 patents.

Frédéric Triebel MD. PhD is the Frédéric Triebel, PhD scientific founder of Immutep S.A. (2001) and has served as the Scientific and Medical Director at Immutep since 2004. Before starting at Immutep, he was Professor of Immunology at Paris University. While working at Institut Gustave Roussy (IGR), a large cancer centre in Paris, he discovered the LAG-3 gene in 1990 and has continued working on this research program since then; identifying the functions and medical usefulness of this molecule. He headed a research group at IGR while also being involved in the biological follow-up of cancer patients treated in Phase I/II immunotherapy trials. He was

Commenting on joining the Prima team, Frederic said: “The team is very excited about joining Prima. We believe that the combination of therapies targeting different tumour escape mechanisms is about to change the way we treat a complex disease such as cancer. In immuno-oncology combination is key. The Prima team has expertise with later stage clinical trials and manufacturing and logistics that will really help to leverage the next phase of development for Immutep’s products.”

==> picture [596 x 281] intentionally omitted <==

5

==> picture [299 x 71] intentionally omitted <==

Company calendar, social network contacts, fast facts

==> picture [116 x 28] intentionally omitted <==

----- Start of picture text -----

NOVEMBER 2014
----- End of picture text -----

Annual General Meeting

Prima BioMed – Fast Facts

Listings

Australian Securities Exchange (ASX), NASDAQ, Deutsche Börse

Stock Codes

ASX: PRR, NASDAQ: PBMD, Deutsche Börse: ISIN: US74154B2304

Follow Prima’s progress

Prima BioMed is dedicated to maintaining consistent and clear communications with our investors. In addition to our quarterly newsletter, we encourage our shareholders to continue following Prima’s progress in a number of ways:

Issued Capital – Ordinary shares

1.26B (approximate as of 2 October 2014)

Issued ADR’s

2.70M (approximate as of 30 September 2014)

Market Capitalization

[www.primabiomed.com.au]

The company website is a treasure trove for those in search of details about our company, our management team, and archived information. We encourage everyone to check it out regularly.

A$49.15M (approximate as of 7 October 2014)

Cash Position

A$23.2M (approximate as of 30 June 2014)

[www.clinicaltrials.gov] Prima registers all of our clinical trials, and the details of enrolling doctors, on the ClinicalTrials.gov website, a service of the United States National Institutes of Health. This register is the largest such repository of clinical trial information around the world.

[Twitter ]

Board of Directors

Ms Lucy Turnbull, AO Non-executive Chairman

twitter.com/PrimaBioMed

[Facebook ]

www.facebook.com/PrimaBioMed

Mr Albert Wong Mr Marc Voigt

Non-executive Deputy Chairman Chief Executive Officer and Executive Director

[LinkedIn]

http://us.linkedin.com/company/prima-biomed-ltd

Dr Russell J Howard Mr Pete A Meyers

Non-executive Director

Non-executive Director

Senior Management

Dr Sharron Gargosky Chief Technical Officer

Ms Deanne Miller

General Counsel and Company Secretary

www.primabiomed.com.au

Pictures: page 5: patient + doctor: © Igor Mojzes - fotolia.com, page 3: test tubes: © Africa Studio - fotolia.com Design: brandLOVERS.de Board: Prima BioMed